HALO Stock News & Catalysts – Halozyme Therapeutics

FEATURED

Halozyme Reaffirms It Projects Zero to Minimal Impact to Royalty Revenue Through At Least 2035 Based on Medicare Drug Price Negotiation Program Final Rule for IPAY 2029

SAN DIEGO, Nov. 6, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme" or the "Company") today confirmed that the Company expects zero to minimal royalty revenue impact based on

Summary

Nov 6, 2026, 10:04 AM ·PRNewswire

RECENT

U.S. FDA Approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Co-Formulated with Halozyme's ENHANZE® Technology for the Treatment of Advanced Head and Neck Cancer

Approval extends RYBREVANT FASPRO's well-established, dual-targeted benefit beyond lung cancerSAN DIEGO, Nov. 6, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) (Halozyme) today announced that Johnson

Nov 6, 2026, 9:57 AM ·PRNewswire

HALOZYME REPORTS THIRD QUARTER 2026 RESULTS AND RAISES FULL YEAR 2026 FINANCIAL GUIDANCE

Total Revenue Increased 39% YOY to $493 millionRoyalty Revenue Increased 44% YOY to $341 millionRaising 2026 Financial Guidance Ranges:Total Revenue of $1.860 - $1.925 billion, YOY Growth of 33% - 38%Royalty Revenue of

Nov 5, 2026, 4:05 PM ·PRNewswire

Halozyme to Report Third Quarter 2026 Financial and Operating Results

SAN DIEGO, Oct. 22, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced it will release its third quarter 2026 financial and operating results on Thursday, November 5,

Oct 22, 2026, 8:30 AM ·PRNewswire

Halozyme Wins Injunction Stopping Manufacture and Sale of Merck's Keytruda SC in Multiple European Markets

SAN DIEGO, Oct. 7, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme" or the "Company") announced today that the specialized Dutch patent court of the Hague has found Merck to be

Oct 7, 2026, 8:30 AM ·PRNewswire

Halozyme Announces Expansion of Global Collaboration and License Agreement with argenx to Support the Development of Subcutaneous Formulations for Two Additional Exclusive Targets Using its ENHANZE® Technology

Expanded agreement increases argenx's exclusive access to ENHANZE® from six to eight targetsSAN DIEGO, Oct. 6, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme" or the

Oct 6, 2026, 4:05 PM ·PRNewswire

Halozyme Announces Appointment of Jim Daly to its Board of Directors

SAN DIEGO, Sept. 30, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme" or the "Company") today announced the appointment of James "Jim" Daly to its Board of Directors.

Sep 30, 2026, 4:05 PM ·PRNewswire

Halozyme Therapeutics, Inc. Announces Pricing of Upsized Private Offering of $1.3 Billion of Convertible Senior Notes due 2033

SAN DIEGO, Sept. 17, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme" or the "Company"), today announced the pricing of $1.3 billion aggregate principal amount of 1.50%

Sep 17, 2026, 11:20 PM ·PRNewswire

Halozyme Therapeutics, Inc. Announces Proposed Offering of $1.05 Billion of Convertible Senior Notes due 2033

SAN DIEGO, Sept. 16, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme" or the "Company"), today announced that it intends to offer, subject to market conditions and other

Sep 16, 2026, 4:30 PM ·PRNewswire

Halozyme to Participate at Upcoming Investor Conferences

SAN DIEGO, Sept. 2, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced that Dr. Helen Torley, President and Chief Executive Officer, and Darren Snellgrove, Chief

Sep 2, 2026, 8:30 AM ·PRNewswire

Halozyme Appoints Dannielle Appelhans to its Board of Directors

SAN DIEGO, Aug. 18, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced the election of Dannielle Appelhans to its Board of Directors. Ms. Appelhans brings more than 20

Aug 18, 2026, 4:01 PM ·PRNewswire

HALOZYME REPORTS RECORD SECOND QUARTER 2026 RESULTS, BEATS ESTIMATES AND RAISES FULL YEAR 2026 FINANCIAL GUIDANCE

Total Revenue Increased 48% YOY to $481 millionRoyalty Revenue Increased 50% YOY to $308 millionRaises 2026 Financial Guidance Ranges:Total Revenue of $1.835 - $1.910 billion, YOY Growth of 31% - 37%Royalty Revenue of

Aug 6, 2026, 4:01 PM ·PRNewswire

Halozyme to Report Second Quarter 2026 Financial and Operating Results

SAN DIEGO, July 23, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced it will release its second quarter 2026 financial and operating results on Thursday, August 6,

Jul 23, 2026, 8:30 AM ·PRNewswire

Halozyme Announces Global Collaboration and License Agreement with Incyte to Support the Development of Subcutaneous Formulations of INCA033989 Using its ENHANZE® Technology

Agreement provides Incyte the rights to develop and commercialize ENHANZE® with its mutCALR development program and an option to nominate up to two additional targetsSAN DIEGO, July 20, 2026 /PRNewswire/ -- Halozyme

Jul 20, 2026, 8:00 AM ·PRNewswire

Halozyme Appoints David Ramsay as President Drug Delivery

SAN DIEGO, June 30, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme" or the "Company") today announced the appointment of David Ramsay as President Drug Delivery, effective June

Jun 30, 2026, 4:02 PM ·PRNewswire

Halozyme Therapeutics, Inc. HALO · News